JAMA Otolaryngology—Head & Neck Surgery

12/12/2025

Despite significant reductions in discharge opioid prescriptions from 2017 to 2023, refill rates did not decline. Aligning discharge opioid doses closely with final inpatient opioid use, controlling perioperative pain, and monitoring prior refill patterns may help reduce persistent opioid use after otolaryngology–head and neck surgery. https://ja.ma/4oJcgTP

12/11/2025

In this episode of the JAMA Otolaryngology Head & Neck Surgery Author Interviews podcast, Paul Bryson, MD, speaks with Molly Huston, MD, associate professor at Wash U Medicine and director of the Voice and Airway Center, and Will Strober, MD, resident physician at Wash U Medicine, about approaches to treating inducible laryngeal obstruction and findings from their randomized trial of biofeedback vs respiratory retraining.

Listen now:

Interview with Molly N. Huston, MD, and William A. Strober, MD, MSCI, authors of Biofeedback vs Respiratory Retraining for Inducible Laryngeal Obstruction: A Randomized Clinical Trial. Hosted by Paul C. Bryson, MD, MBA.

12/11/2025

A randomized clinical trial found that video biofeedback and respiratory retraining therapy were similarly effective for inducible laryngeal obstruction, with both groups reporting some symptom improvement but few achieving clinically meaningful change. Biofeedback offers added advantages of accessibility and no additional cost.

https://ja.ma/3XOoboC

12/04/2025

A cohort study developed and validated a serum metabolite-based prognostic scoring system (MetaboScore) to predict recurrence risk in oral cavity squamous cell carcinoma ( ) among patients with resected, advanced-stage disease and high betel quid exposure.

The MetaboScore, comprising 19 metabolites, was independently associated with increased risk of local, regional, and distant recurrence, as well as lower disease-free and disease-specific survival, beyond conventional staging. https://ja.ma/442VYxN

12/04/2025

Among patients with treated with radiotherapy, each additional week of treatment interruption was associated with decreased three-year locoregional control and survival, regardless of p16 status.

The magnitude of the association varied, with the largest detriment observed in patients with locally advanced, p16-negative disease, emphasizing the clinical relevance of uninterrupted radiotherapy scheduling in HNSCC. https://ja.ma/4rBSL2m

12/03/2025

Use of glucagon-like peptide-1 receptor agonists ( ) in adults with type 2 was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.

https://ja.ma/4ohY3gm

12/03/2025

Model-based analysis of ECAPs in users showed stronger auditory nerve responses and plasticity in younger recipients, highlighting the value of early implantation. https://ja.ma/44M62LL

12/02/2025

Head and neck cancer (HNC) is a collective term for cancers affecting the oral cavity, pharynx, larynx, salivary glands, and other sites in the head and neck region.

Approximately 90% of HNCs are squamous cell carcinomas (ie, HNSCCs), which arise from the epithelial lining of the upper aerodigestive tract. HNC is the seventh most prevalent cancer type, accounting for more than 926 000 cases and 507 600 deaths annually.

This Review explores the application of immunotherapy within the salvage setting for locally advanced, recurrent disease.

https://ja.ma/3Xj2xIQ

11/30/2025

Use of glucagon-like peptide-1 receptor agonists ( ) in adults with type 2 was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.

https://ja.ma/48zXMAO

11/30/2025

Otolaryngologists face increasing workload, complexity, and stakes akin to elite athletes, yet mental skills training remains underused.

This Special Communication explores how mental training techniques found in sports psychology may be used by otolaryngologists to optimize surgical performance and surgeon well-being.

https://ja.ma/3JWHIQt

11/28/2025

On December 1 at 10 AM ET, JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new World Health Organization (WHO) guideline concerning -1 therapy and adults with .

Register for the webinar: https://ja.ma/4p3nRhu

11/28/2025

Use of glucagon-like peptide-1 receptor agonists ( ) in adults with type 2 was associated with an increased risk of new chronic cough compared with other second-line diabetes medications.

https://ja.ma/49ATQAV